Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction

Philip J Keeling, Stephen Jeffery, Alida L P Caforio, Rohan Taylor, Gian F Bottazzo, Michael J Davies, William J McKenna

Abstract

**Objective**—To assess the prevalence and significance of enteroviral genome within myocardial biopsy specimens taken from patients with idiopathic dilated cardiomyopathy and from controls.

**Design**—Prospective evaluation of myocardial tissue for the presence of an enteroviral genome by the polymerase chain reaction.

**Setting**—A tertiary referral centre for patients with idiopathic dilated cardiomyopathy.

**Patients**—Tissue for the study came from 50 consecutive patients with dilated cardiomyopathy, 41 with other forms of heart disease and 34 from coroners' necropsy cases.

**Results**—Enteroviral genome was detected in 6/50 (12%) patients with dilated cardiomyopathy and 13/75 (17%) of the controls (not significant). No differences were seen between dilated cardiomyopathy patients with or without myocardial enteroviral genome in respect of age; duration of symptoms; proportion of patients with a premonibor acute viral illness, excess alcohol consumption, or hypertension; New York Heart Association functional class; measures of left ventricular function; or endomyocardial histology. Within the control group enteroviral genome was detected in 3/15 (20%) patients with ischaemic heart disease, 2/19 (10.5%) with valvar heart disease, 1/5 (20%) with specific heart muscle disease, 0/2 (0%) with congenital heart disease, and 7/34 (20.6%) cases of sudden death. During 2–52 month follow up (mean 22) 15/44 (34%) patients without myocardial enteroviral genome and 2/6 (33%) with myocardial enteroviral genome died suddenly or required orthotopic heart transplantation for progressive heart failure.

**Conclusions**—These findings do not support the hypothesis that persistent enteroviral infection is of pathogenic or prognostic importance in dilated cardiomyopathy but they are consistent with enterovirus being a common environmental pathogen.

Enteroviruses, particularly coxsackie B viruses, are thought to be important in the pathogenesis of myocarditis and idiopathic dilated cardiomyopathy. Although there is considerable support for an aetiological role of coxsackie virus in murine myocarditis and dilated cardiomyopathy direct evidence in man is lacking. The principal supporting evidence linking enteroviral infection to dilated cardiomyopathy is derived from several retrospective serological studies. Enteroviruses, however, are endemic pathogens and enteroviral serology is highly complex; despite the introduction of specific assays for enteroviral immunoglobulin M the significance of positive enteroviral serology remains unclear. Recombinant deoxyribonucleic acid technology has been used to detect viral genome within myocardial biopsy material from patients with dilated cardiomyopathy and myocarditis. Initial studies of slot blot hybridisation suggested that enteroviral genome was present in more than 50% of patients with established cardiomyopathy. Other groups, with different hybridisation techniques, have failed to confirm such a high prevalence of enteroviral genomic material in biopsy specimens from patients with myocarditis or dilated cardiomyopathy and accumulated data suggest a prevalence of 10–20%. The discrepancies in the results of these studies may reflect differences in clinical diagnosis and the variable sensitivity and specificity of hybridisation assays used.

Gene amplification by the polymerase chain reaction (PCR) is a rapid and extremely sensitive technique. Jin et al, using an enteroviral specific polymerase chain reaction in combination with slot blot hybridisation, reported a low prevalence (10%) of enteroviral genome within the myocardium of patients with dilated cardiomyopathy and myocarditis. Unfortunately the low number of controls in this study makes interpretation of these results extremely difficult. In our study, we report the application of an enterovirus specific
PCR gene amplification technique to myocardial biopsy specimens taken from 50 patients with clinical dilated cardiomyopathy and from 75 biopsy specimens taken from patients with other forms of cardiac disease or cases of sudden death in the community.

Patients and methods

Patients

Dilated cardiomyopathy

A clinical diagnosis of dilated cardiomyopathy was made according to World Health Organisation (WHO) criteria in 50 patients (38 men, 12 women) whose ages ranged from 17–60 (mean (SD), 40 (12)) years. Fifteen patients had a history of chronic excess alcohol consumption (men > 8 units a day and women > 6 units a day for the preceding five years) and nine patients had a history of hypertension and were included in the study. All patients had an enlarged left ventricle on echocardiography (mean left ventricular end diastolic size 68 (8) mm) when expressed as a percentage of the calculated normal size by the method of Henry et al (mean 143% (19)% (normal range <112%)). All patients had impaired left ventricular systolic function as assessed by echocardiography (fractional shortening 13% (7)%), angioraphy (ejection fraction 28% (8)% and radionuclear ventriculography (ejection fraction 23% (8)%). Functional classification with the New York Heart Association (NYHA) classification showed 24 patients were in class I, seven in class II, 16 in class III, and three in class IV. Right ventricular endomyocardial-biopsies were taken transvenously in all patients and samples were taken at the time of cardiac transplantation from the explanted heart of six patients. Biopsies were sectioned, stained with haematoxylin and eosin, and assessed by light microscopy with the Dallas criteria. Due to the absence of diagnostic features on histology in dilated cardiomyopathy those biopsies in which there was fibrosis in the absence of an inflammatory cell infiltration were termed established dilated cardiomyopathy.

Controls

Seventy five myocardial control tissues were taken, mostly at the time of cardiac surgery, from patients with valvar disease (n = 19), coronary artery disease (n = 15), congenital heart disease (n = 2), or specific heart muscle disorders (hypertrophic cardiomyopathy (n = 3), cardiac amyloidosis (n = 1), right ventricular dysplasia (n = 1). Additional cardiac control tissue (n = 34) was taken at the time of coroner’s necropsy from people who died suddenly. Although 12 of these deaths were due to myocardial infarction, 24 cases had no cardiac pathology and died from non-cardiac causes (violent deaths (n = 6); cerebrovascular accident (n = 5); carcinoma (n = 4); pulmonary embolism (n = 3); unknown (n = 6). Most samples were taken from the right ventricular septum.

ENTEROVIRAL SPECIFIC GENE AMPLIFICATION BY THE POLYMERASE CHAIN REACTION

The polymerase chain reaction is a recent development in molecular hybridisation technology, which enables a minute quantity of specific nucleic acid to be detected within a clinical sample after its extensive and selective amplification. In this assay total cellular ribonucleic acid was extracted from biopsy specimens and used to synthesise the more stable complementary deoxyribonucleic acid that is used in the subsequent polymerase chain reaction. With specially designed and enteroviral specific oligonucleotide primers, a region of the enteroviral complementary deoxyribonucleic acid was selectively amplified by the polymerase chain reaction. The amplified fragment of deoxyribonucleic acid then underwent gel electrophoresis and was transferred to a membrane that was hybridised with a radiolabelled enterovirus specific deoxyribonucleic acid probe and was then filmed by autoradiography.

Preparation of ribonucleic acid from myocardial samples

Endomyocardial samples were immediately snap frozen and stored in liquid nitrogen until required. Intact ribonucleic acid was extracted with RNA Agents (Promega) from myocardial biopsy specimens by the one step procedure of Chomczynski and Sacchi. Briefly, specimens were denatured and homogenised in guanidine thiocyanate with citrate/sarcosine/β-mercaptoethanol buffer. Ribonucleic acid was extracted with phenol and chloroform and precipitated twice with isopropanol. The ribonucleic acid was then washed in 75% ethanol, vacuum dried, and stored under 100% ethanol at −70°C until required. Before use these samples were centrifuged at 4°C and then resuspended in 10μl of RNAase free water. The quality of the ribonucleic acid was checked by northern blotting with a radiolabelled probe to actin and by absorbance spectrophotometry (A260/280).

Preparation of coxsackie virus positive control ribonucleic acid

Coxsackie virus ribonucleic acid was prepared as a positive control from a stock of Coxsackie B3 virus (10⁶ infectious agents/μl) harvested in phosphate buffered saline (PBS) from infected Vero cells when 50% of the cells exhibited cytopathic effects. Cells were suspended in guanidine solution and ribonucleic acid was extracted as above.

Oligonucleotides

Enteroviruses show a high degree of nucleotide sequence homology and the oligonucleotides used in this assay have previously been shown to be highly specific for enteroviral genome and capable of detecting a broad range of enteroviruses. The structures of this primer pair (E1 and E2) and the hybridisation probe E3 have been published previously and gene amplification has been shown to be enterovirus specific and produce a 196 base-pair fragment.
Viral complementary deoxyribonucleic acid synthesis and the polymerase chain reaction

First strand complementary deoxyribonucleic acid synthesis and subsequent polymerase chain reaction gene amplification was performed with the Perkin-Elmer Cetus Gene-Amp Kit. First strand complementary deoxyribonucleic acid synthesis was achieved in a total volume of 20μl by random hexamers using 2μl of sample material and 50 U moloney murine leukemia virus reverse transcriptase. The final concentration of magnesium used was 3.75 mM. These mixtures were left at room temperature for 10 minutes, then incubated at 42°C for 15 minutes, 99°C for five minutes, and finally for five minutes at 5°C. The polymerase chain reactions were performed in a total volume of 100μl using 1U AmpliTaq (Perkin-Elmer Cetus) and 1μl each of a primer pair (E1 and E2, concentration 80 mg/ml) with a final magnesium concentration of 2-35 mM. The mixtures were incubated at 95°C for two minutes and then step cycled in a two temperature cycle with one minute at 95°C and one minute 60°C for 55 cycles and finally incubated for seven minutes at 60°C (Techne PHC-1). Amplified products were stored at −20°C until required. In each assay coxsackie virus positive samples and two negative samples, one with ribonucleic acid extracted from a normal myocardium and one containing no ribonucleic acid, were used as controls.

**Gel electrophoresis and Southern blotting**

A total of 15μl of amplification product underwent electrophoresis at 100 V in 1% 1:5% agarose gels in TBE (110g Tris, 55g boric acid/l, 20 ml 1 M EDTA). Gels were stained with ethidium bromide to detect deoxyribonucleic acid by illumination with ultraviolet light. The deoxyribonucleic acid was transferred to Hybond-N+ membranes (Amersham) with 0.4 M sodium hydroxide as the alkali transfer buffer. One hundred ng of E3 was end labelled with [γ-32P]ATP by T4 polynucleotide kinase. Membranes were prehybridised for 30 minutes and hybridised for two hours at 37°C, in 10 ml 20 × SSPE (3M sodium chloride, 0.18M sodium hydrogen phosphate, 0.018M EDTA), 2 ml 100 × Denharts’ solution (Ficoll 1%, polyvinylpyrrolidone 1%, bovine serum albumin 1%) and 2 ml 10% sodium dodecyl sulphate (SDS) made up to 40 ml in distilled water. The membranes were washed in 2 × SSC with 0.1% SDS at 50°C and then exposed overnight to an x ray film at −70°C with intensifying screens. To assess the sensitivity of the assay 10-fold serial dilutions of virus were prepared and 10 to 10^6 virions added to biopsy material from entero virus negative myocardium. The ribonuclease from these specimens was then extracted with subsequent complementary deoxyribonucleic acid synthesis, polymerase chain reaction gene amplification, gel electrophoresis, and Southern blotting.

**Statistical analysis**

Statistical analyses were performed with the Fisher’s exact test with Yates’s correction. Values are expressed as mean (SD) with p < 0.05 being considered significant.

**Results**

**The polymerase chain reaction assay**

First strand complementary deoxyribonucleic acid synthesis with random hexamers produced more intense bands than did the use of the specific downstream primer (E1). The polymerase chain reaction had highly specific gene amplification with stringent annealing conditions, no extension cycle, and low enzyme concentrations. This allowed completion of the large number of step cycles without undue non-specific gene amplification. Some assays with control tissue did produce non-specific gene amplification products. Further analysis of these samples showed that three to four times as much ribonucleic acid had been extracted and used in the assay and this non-specific gene amplification could be reduced with smaller amounts of ribonucleic acid in the assay. Gel electrophoresis of amplified product alone produced clear bands at 196 base pairs in 15 assays. Subsequent Southern blotting confirmed that these bands hybridised with radiolabelled E3. In some assays a significant degree of non-specific hybridisation with genomic ribonucleic acid and complementary deoxyribo-
Table 1  Clinical features and results of enteroviral polymerase chain reaction in patients with dilated cardiomyopathy (mean (SD))

<table>
<thead>
<tr>
<th>Entero viral genome</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (n = 50)</td>
<td>6</td>
<td>44</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>45 (16)</td>
<td>40 (12)</td>
</tr>
<tr>
<td>Duration of symptoms (months)</td>
<td>59 (58)</td>
<td>35 (40)</td>
</tr>
<tr>
<td>NYHA class (n)</td>
<td>1 (3), II (3), II (7), III (13), IV (-3)</td>
<td></td>
</tr>
<tr>
<td>Acute viral illness &lt;6 months</td>
<td>1 (17%)</td>
<td>11 (25%)</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>69 (10)</td>
<td>68 (9)</td>
</tr>
<tr>
<td>LVEDD%</td>
<td>14 (17)</td>
<td>13 (7)</td>
</tr>
<tr>
<td>FS (%)</td>
<td>13 (9)</td>
<td>13 (7)</td>
</tr>
<tr>
<td>Histology*</td>
<td>Established 6, Established 21, normal 15, myocarditis 2, healing myocarditis 2</td>
<td></td>
</tr>
</tbody>
</table>

*According to Dallas criteria.
LVEDD, left ventricular end diastolic dimension; LVEDD%, percentage of calculated left ventricular end diastolic dimension (normal range <112%)7; FS, fractional shortening.

nucleic was found, but this could easily be distinguished from the specific band that hybridised at 196 base-pairs. Furthermore, after Southern blotting a positive hybridisation signal was obtained in four more assays in which no band had been seen initially after gel electrophoresis. The figure shows an agarose gel on which polymerase chain reaction amplified product from patients with dilated cardiomyopathy and control tissues has undergone electrophoresis (fig A), and the corresponding autoradiograph is also shown for direct comparison (fig B). To find the sensitivity of the assay serial dilutions of stock virus were added to biopsy samples and analysed as above. This showed that the assay was capable of detecting less than 10^2 infectious virions in each biopsy specimen.

PATIENTS WITH DILATED CARDIOMYOPATHY

Enteroviral genome was detected in 6/50 (12%) patients with dilated cardiomyopathy. Table 1 gives the clinical and biopsy features of these patients together with the results of the polymerase chain reaction assay. No differences in dilated cardiomyopathy patients with or without myocardial enteroviral genome were noticed in age, duration of symptoms, proportion of patients with a premorbid acute viral illness, excess alcohol consumption, hypertension, NYHA functional class, measures of left ventricular function, or results of endomyocardial histology. During follow up of the six patients with myocardial enteroviral genome, three patients remained unchanged at 7–25 months, one patient was improved at 27 months, one patient received an orthotopic heart transplantation at three months and one patient died suddenly at seven months. During the 2–52 (mean 22) month follow up of 44 patients without myocardial enteroviral genome, six died suddenly and nine received an orthotopic heart transplantation for progressive heart failure. Of the remaining patients 16 remained clinically stable (1 NYHA class I, five NYHA class II), nine had improved (NYHA class I) and two had deteriorated (one NYHA class II, one NYHA class III). No differences were noticed in the clinical outcome between these patients with and without enteroviral genome within the myocardium.

CONTROL PATIENTS

Enterovirus-specific gene amplification by polymerase chain reaction was noted in 13/75 (17.3%) of the control population. This was not significantly different when compared with the results of the dilated cardiomyopathy patients. Subgroup analysis showed the presence of myocardial enteroviral genome in 2/19 (10.5%) with valvular heart disease, 3/15 (20%) with ischaemic heart disease, 1/5 (20%) with specific heart muscle diseases, 0/2 (0%) with congenital heart disease, and 7/34 (20.6%) community sudden deaths including 3/12 (25%) cases who died from myocardial infarction.

Discussion

In this study we applied a highly sensitive and specific polymerase chain reaction technique to detect entero viral genome in myocardial tissue taken from 50 patients with dilated cardiomyopathy and from 75 controls (41 with other forms of heart disease and 34 from coroners' necropsies). Entero viral genome was detected within the myocardium in 6/50 (12%) patients with dilated cardiomyopathy but was not associated with any feature of clinical, histological, or functional assessment. Furthermore, the presence of entero viral genome within the myocardium of these patients did not confer on them an adverse prognosis as has previously been proposed. Our study also showed that entero viral genome was present in myocardial tissues in a similar proportion of controls (17%).

All the patients studied with dilated cardiomyopathy have been extensively characterised with strict diagnostic criteria and are being regularly followed up. The control tissues were taken either at the time of cardiac catheterisation or surgery from coroners' necropsies. The quality of the extracted ribonucleic acid, a particular concern for the necropsy tissues because of its possible degradation after death, was found to be adequate in all groups of patients. The polymerase chain reaction used in this study was highly sensitive and capable of detecting as few as 100 copies of entero viral genome within a single endomyocardial biopsy specimen. The hybridisation probe (E3) used has previously been shown to be pan-enteroviral and capable of detecting a wide range of enteroviruses.
Some non-specific hybridisation with genomic ribonucleic acid or complementary deoxyribonucleic acid was noted but this was easily distinguished from enterviral specific hybridisation after gel electrophoresis and southern blotting of the amplification product.

We found enterviral genome within the myocardium of 12% of patients with dilated cardiomyopathy: similar proportions were reported by other workers who used in situ hybridisation or polymerase chain reaction techniques but less than those reported by Archard et al who used the technique of slot blot hybridisation (table 2). A limitation of slot blot hybridisation is non-specific hybridisation with genomic ribonucleic or deoxyribonucleic acid. This has been recently highlighted by Jin et al who found that before gene amplification under conditions of low stringency, the extracted ribonucleic acid showed considerable non-specific hybridisation with a high number of false positive results. A further problem in several of the reported studies is the differences in selection of patients with dilated cardiomyopathy, and in particular to the presence of previous systemic hypertension or excess alcohol consumption. The finding of enterviral genome within the myocardium of 17% of control tissues has not been reported. Previous studies, however, with sensitive and specific hybridisation techniques, have been limited in the number of control tissues analysed. The only report that has assayed a significant number of control samples with in situ hybridisation has failed to detect enterviral genome within the myocardium. Whether this reflects the lower number of copies of enterviral genome within the control tissues compared with those from patients with dilated cardiomyopathy due to the lower sensitivity of in situ hybridisation remains to be established.

Historically the principal supporting evidence linking enterviral infection to dilated cardiomyopathy is derived from retrospective serological studies. Infection with enteroviruses is common and infection with a single serotype often induces a multitypic response against several different serotypes with most people developing neutralising antibodies to a large range of serotypes early in adult life. Also there is usually considerable uncertainty in finding the time of the start of disease and the preclinical phase of the disease is often very long. The introduction of specific assays for enterviral immunoglobulin M promised to help with the identification of recent or persistent infection. High levels of entervirus specific immunoglobulin M have, however, also been reported in a number of other conditions including chronic relapsing pericarditis and postviral fatigue syndrome as well as in a matched control population taken from the community. Whether there is a difference in the prevalence or persistence of this entervirus specific immunoglobulin M response between patients with dilated cardiomyopathy and a matched control population is not known at present. It is pertinent to remember that type 1 insulin dependent diabetes mellitus and amyotrophic lateral sclerosis were initially linked to enterviral aetiology on the basis of raised enterviral serology, but subsequent studies with appropriate controls have failed to support this claim. Also, a clear association between the presence of enterviral specific immunoglobulin M and the presence of enterviral genome within the myocardium has not been confirmed in patients with dilated cardiomyopathy.

The significance of enterviral genome within the myocardium in the small proportion of patients with dilated cardiomyopathy and its relation to active viral replication is unclear. Perhaps only active viral replication or infection with a particular type of enterovirus is responsible for the development of dilated cardiomyopathy, and this may only occur in patients with dilated cardiomyopathy and not the controls. Markers of active viral replication (for example enterviral capsid protein, VP1) and the application of type specific enterviral antibodies have not been assessed in dilated cardiomyopathy. Also the absence of a clear relation between the presence of viral genome and of histopathological damage within the myocardium has not been shown in humans by in situ hybridisation. It is of course still possible that enterviral infection may be important in pathogenesis of disease by acting as a trigger for the induction of autoimmunity as has been reported in the chronic form of murine myocarditidis. In this circumstance it would perhaps be surprising with highly sensitive hybridisation techniques to find enterviral genomic sequences in the absence of whole competent infectious viruses within the myocardium. The low prevalence of enterviral genome, however, within the myocardium of patients with dilated cardiomyopathy and in a similar proportion of controls does not provide support for a pathogenic role of persistent enterviral infection in dilated cardiomyopathy.

PJ K is a British Heart Foundation research fellow and ALPC is supported by a research fellowship from the European Society of Cardiology. We also acknowledge the helpful comments of Dr Steve Tracy with regard to the ribonucleic acid amplification.

9 Fletcher GF, Coleman MR, Feirino PM, Marine WM, Wonger NZ. Viral antibodies in patients with primary
Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction

Philip J Keeling, Stephen Jeffery, Alida L P Caforio, Rohan Taylor, Gian F Bottazzo, Michael J Davies and William J McKenna

Br Heart J 1992 68: 554-559
doi: 10.1136/hrt.68.12.554